Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report, filed on January 23, 2026, covers the month of January 2026 for Haoxi Health Technology Limited, a Cayman Islands exempted company. The filing discloses the execution of a new capital raising mechanism rather than reporting periodic financial results.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The primary financial metric disclosed relates to the potential capital raise:
- Maximum Offering Size: Up to $80,000,000 in aggregate offering price.
- Security Type: Class A ordinary shares, par value $0.0025 per share.
- Transaction Costs: 2.5% commission on gross proceeds payable to the sales agent.
- Expense Reimbursement: Up to $75,000 annually for specified expenses.
Material Changes
The material change reported is the entry into a Sales Agreement with Aegis Capital Corp. as the sales agent. This agreement establishes an "At The Market" (ATM) offering program, allowing the company to sell shares from time to time based on market conditions and company instructions. This program is supported by a shelf registration statement (File No. 333-287686) declared effective on June 13, 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding operational performance. The document notes standard legal contingencies, including customary indemnification rights for the sales agent and the requirement that sales comply with applicable state and federal laws. No unusual items or specific risk factors beyond standard securities law compliance are detailed in this summary.
Key Facts for Investor Verification
- Verify the current market price of Class A ordinary shares to assess the potential dilution impact of the $80 million ATM program.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific price, time, or size limits the company may impose on sales.
- Confirm the company's current cash position and debt levels in the most recent Form 20-F to understand the necessity of this capital raise.
- Monitor future filings for actual sales notices and proceeds generated under this agreement.